Breakthrough T1D & NIH Workshop at the Intersection of Immunology and Bioengineering
Breakthrough T1D and NIH bring together top scientists and engineers to strategize on how to allow implanted beta cells to thrive.
Kid-Approved Back-to-School T1D-Friendly Recipes
Tasty, easy-to-make diabetes-friendly treats for school lunches, after school snacks, and school night dinners.
Abbott FreeStyle Libre 2 iOS App Receives FDA Approval
On August 2, 2021, Abbott announced the FreeStyle Libre 2 iOS app received approval from the FDA for adults and children ages 4 and up with diabetes.
FDA Approves Semglee® as the First Interchangeable Biosimilar Insulin Product
The U.S. Food and Drug Administration (FDA) approved Semglee® (insulin glargine-yfgn) as the first ever interchangeable biosimilar insulin product. Semglee® (insulin glargine-yfgn) is indicated to improve glycemic control in adults and pediatric people with type 1 and adults with type 2 diabetes, and is biosimilar and interchangeable to Lantus®, a long-acting insulin. In other words, […]
Two Studies Shed Light on Diabetic Kidney Disease
Two recent publications shed light on which people with type 1 diabetes will develop end-stage kidney disease, a complication of diabetes.
On Medicare? Accessing CGMs Just Got Easier
A recent update to continuous glucose monitor (CGM) coverage requirements will make it easier for people covered by Medicare to access CGM technology.
Eli Lilly Acquires Breakthrough T1D T1D Fund Portfolio Company Protomer Technologies
Breakthrough T1D is excited to announce that the T1D Fund portfolio company Protomer Technologies, who is developing "smart" insulin, has been acquired by Eli Lilly.
Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning that it has not been approved at this time.
At ADA, Breakthrough T1D-Funded Research Takes Center Stage
There were a number of fantastic results at the ADA’s Scientific Sessions. Here is a video and a summary of the key takeaways from the conference.
Marilyn and Gerald Fishbone: A Lifetime of Generosity and Service
Marilyn and Gerald Fishbone know first-hand how incredible research changes the lives of people with type 1 diabetes (T1D). For more than 50 years, they have been pillars in the T1D community dedicating their lives to helping advance innovative research. Marilyn remembers the day their 18-month-old son, Scott, was diagnosed. It was 1969. “I had […]
